A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular …
H Yanai, H Adachi, M Hakoshima, S Iida, H Katsuyama - Cells, 2024 - mdpi.com
The reabsorption of uric acid (UA) is mainly mediated by urate transporter 1 (URAT1) and
glucose transporter 9 (GLUT9) in the kidneys. Dotinurad inhibits URAT1 but does not inhibit …
glucose transporter 9 (GLUT9) in the kidneys. Dotinurad inhibits URAT1 but does not inhibit …
Celebrating Versatility: Febuxostat's Multifaceted Therapeutic Application
KI Kraev, MG Geneva-Popova, BK Hristov, PA Uchikov… - Life, 2023 - mdpi.com
Febuxostat, initially developed as a xanthine oxidase inhibitor to address hyperuricemia in
gout patients, has evolved into a versatile therapeutic agent with multifaceted applications …
gout patients, has evolved into a versatile therapeutic agent with multifaceted applications …
A New Avenue for Enhanced Treatment of Hyperuricemia and Oxidative Stress: Design, Synthesis and Biological Evaluation of Some Novel Mutual Prodrugs Involving …
Febuxostat (FEB) is the first non-purine xanthine oxidase inhibitor (XOI) used for the
treatment of hyperuricemia and gout. The oxidative stress induced by reactive oxygen …
treatment of hyperuricemia and gout. The oxidative stress induced by reactive oxygen …
Therapeutic effects of allopurinol on the function of left ventricular and activity of matrix metalloproteinase enzymes (MMPs) in patients with chronic heart failure
H Deng, Q Li, D Zhu - Cellular and Molecular Biology, 2022 - cellmolbiol.org
Heart failure is a growing public health problem, especially in the elderly, often occurring
due to ischemia and coronary artery disease. Allopurinol can protect against myocardial …
due to ischemia and coronary artery disease. Allopurinol can protect against myocardial …
Allopurinol Use and the Risk of Type 2 Diabetes Mellitus: A Meta-Analysis of Cohort Studies
Objective To assess whether there is a relation between allopurinol use and the probability
of type 2 diabetes mellitus (T2DM) in persons with gout and/or hyperuricemia. Methods …
of type 2 diabetes mellitus (T2DM) in persons with gout and/or hyperuricemia. Methods …
A feasible HPTLC method for concurrent quantitation of allopurinol-montelukast co-therapy in plasma and evaluation of their hepatic and renal effects in rats …
Recent studies presented the crucial role of montelukast (MON, a leukotriene receptor
antagonist) against gouty arthritis and its protective effect on drug-induced liver and kidney …
antagonist) against gouty arthritis and its protective effect on drug-induced liver and kidney …